State of Alaska Department of Revenue Acquires Shares of 76,130 TG Therapeutics, Inc. (NASDAQ:TGTX)

State of Alaska Department of Revenue purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 76,130 shares of the biopharmaceutical company's stock, valued at approximately $1,780,000.

Several other large investors also recently made changes to their positions in TGTX. Marshall Wace LLP purchased a new position in TG Therapeutics during the second quarter valued at approximately $36,501,000. Hood River Capital Management LLC purchased a new position in shares of TG Therapeutics during the 1st quarter valued at $22,420,000. Point72 Asset Management L.P. acquired a new position in shares of TG Therapeutics in the second quarter worth $10,423,000. Assenagon Asset Management S.A. purchased a new stake in shares of TG Therapeutics during the second quarter worth $8,698,000. Finally, Point72 Europe London LLP acquired a new stake in TG Therapeutics during the second quarter valued at $2,860,000. Institutional investors own 58.58% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TGTX. The Goldman Sachs Group raised their price objective on TG Therapeutics from $18.00 to $20.00 and gave the company a "neutral" rating in a research note on Wednesday, August 7th. HC Wainwright restated a "buy" rating and issued a $49.00 price objective on shares of TG Therapeutics in a research note on Wednesday, September 18th. B. Riley raised their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a research note on Wednesday, August 7th. Finally, TD Cowen started coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price on the stock. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $36.33.

TG Therapeutics Stock Performance

TGTX stock traded up $1.84 on Friday, reaching $26.90. 5,726,750 shares of the company were exchanged, compared to its average volume of 2,430,249. The firm has a market capitalization of $4.16 billion, a PE ratio of 44.10 and a beta of 2.19. TG Therapeutics, Inc. has a 12 month low of $9.81 and a 12 month high of $26.99. The stock's fifty day moving average price is $23.51 and its 200 day moving average price is $20.05. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The business had revenue of $73.47 million during the quarter, compared to analyst estimates of $65.92 million. During the same quarter in the prior year, the business earned ($0.34) earnings per share. The firm's revenue for the quarter was up 357.0% on a year-over-year basis. On average, research analysts anticipate that TG Therapeutics, Inc. will post 0.13 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.